You are here:

Archived: rufinamide 100mg, 200mg and 400mg tablets (Inovelon)

Advice

Following a full submission

rufinamide (Inovelon®) is not recommended for use within NHS Scotland as adjunctive therapy in the treatment of seizures associated with Lennox-Gastaut syndrome in patients four years and older.

The manufacturer did not present a sufficiently robust economic analysis to gain acceptance by SMC.

The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: rufinamide 100mg, 200mg and 400mg tablets (Inovelon)
SMC Drug ID: 416/07
Manufacturer: Eisai Ltd
Indication: seizures associated with Lennox–Gastaut syndrome (LGS) as adjunctive therapy in patients four years and older
BNF Category:
Sub Category: 4.8 Antiepileptic drugs
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 12 November 2007

Current Advice

Resubmission 10 November 2008

Back